Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation-Reference-Cited by-同舟云学术

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

Published:2023-11-16 Issue:1 Volume:45 Page:
ISSN:1064-1963
Container-title:Clinical and Experimental Hypertension
language:en
Short-container-title:Clinical and Experimental Hypertension

Author:

Tang Luxun¹,Cai Qi²,Wang Xiao¹,Li Xiaoyu¹,Li Xiuchuan¹,Chen Lianglong²,Yang Yongjian¹

Affiliation:

1. Department of Cardiovascular Medicine, The General Hospital of Western Theater Command PLA, Chengdu, China

2. Department of Cardiology, Fujian Medical Center for Cardiovascular Diseases, Fujian Institute of Coronary Heart Disease, Fujian Medical University Union Hospital, Fuzhou, China

Funder

Natural Science Foundation of Sichuan Province

General Hospital of Western Theater Command

Popularization and Application Project of Sichuan Health Commission

Publisher

Informa UK Limited

Subject

General Medicine,Physiology,Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10641963.2023.2278205

Reference25 articles.

1. Magnesium lithospermate B ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and its potential targets

2. Molecular genetic framework underlying pulmonary arterial hypertension

3. Diagnosis and Treatment of Pulmonary Arterial Hypertension

4. Clinical trial design and new therapies for pulmonary arterial hypertension

5. AMPKα2 deficiency exacerbates hypoxia-induced pulmonary hypertension by promoting pulmonary arterial smooth muscle cell proliferation

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of CIRBP represses the proliferation and migration of vascular smooth muscle cells via inhibiting Rheb/mTORC1 axis;Biochemical and Biophysical Research Communications;2024-09

2. Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation;Acta Pharmacologica Sinica;2024-05-08

3. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling;Drug Design, Development and Therapy;2024-03

4. Research Progress in Pulmonary Hypertension;Advances in Clinical Medicine;2024